Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
What's Your Reaction?
like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0
